Abstract: Recent years have witnessed much progress in both basic research and clinical trials regarding cancer immunotherapy with chimeric antigen receptor (CAR)engineered T cells. CAR combine the variable regions of a specific monoclonal antibody (scFv) with the CD3ζ endodomain.The extracellular domain of CARengineered T cells directly dock to the tumorassociated antigen (TAA). When T cells bind to target antigens，they mediated redirected cytotoxicity and secrete a series of cytokines such as Perforin, Granzyme, Interferonγ （IFNγ）and Tumor necrosis factorα （TNFα）,  which would eventually lead to the necrosis of tumor cells. Although the antitumor response of the CARengineered T cells is considered as successful and surprising, it should be noted that some safety issues have been observed in other several basic researches and clinical trials. This overview focuses upon the utility and safety of the CARengineered T cells.

Key words: Neoplasms, Immunotherapy, Chimeric antigen receptor